131060Formulation of VZV to protect virus during manufacture and generate a thermo-stable vaccine to ensure market supplyClosedFeasibility StudiesInnovate UKVaricella Zoster virus (VZV) is the causative agent of shingles and chicken pox. The live attenuated VZV vaccine is susceptibe to degradation during its manufacture representing a significant technical formulation challenge that is limiting the broader use of the vaccine, as well as impacting on its cost. Stabilitech has a novel stabilisation platform which has the potential to protect fragile vaccines and biologics during processing and storage. We propose to undertake experimental studies with VZV to determine a novel formulation which will protect the virus during processing, providing a higher titre and more product, and enable storage of the vaccine product at ambient temperature, impacting on the whole supply chain and relieving the pressure on product supplies.